Supreme activity of gramicidin S against resistant, persistent and biofilm cells of staphylococci and enterococci.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
29 11 2019
Historique:
received: 05 07 2019
accepted: 06 11 2019
entrez: 1 12 2019
pubmed: 1 12 2019
medline: 11 11 2020
Statut: epublish

Résumé

Three promising antibacterial peptides were studied with regard to their ability to inhibit the growth and kill the cells of clinical strains of Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. The multifunctional gramicidin S (GS) was the most potent, compared to the membranotropic temporin L (TL), being more effective than the innate-defence regulator IDR-1018 (IDR). These activities, compared across 16 strains as minimal bactericidal and minimal inhibitory concentrations (MIC), are independent of bacterial resistance pattern, phenotype variations and/or biofilm-forming potency. For S. aureus strains, complete killing is accomplished by all peptides at 5 × MIC. For E. faecalis strains, only GS exhibits a rapid bactericidal effect at 5 × MIC, while TL and IDR require higher concentrations. The biofilm-preventing activities of all peptides against the six strains with the largest biofilm biomass were compared. GS demonstrates the lowest minimal biofilm inhibiting concentrations, whereas TL and IDR are consistently less effective. In mature biofilms, only GS completely kills the cells of all studied strains. We compare the physicochemical properties, membranolytic activities, model pharmacokinetics and eukaryotic toxicities of the peptides and explain the bactericidal, antipersister and antibiofilm activities of GS by its elevated stability, pronounced cell-penetration ability and effective utilization of multiple modes of antibacterial action.

Identifiants

pubmed: 31784584
doi: 10.1038/s41598-019-54212-z
pii: 10.1038/s41598-019-54212-z
pmc: PMC6884456
doi:

Substances chimiques

Anti-Bacterial Agents 0
Gramicidin 1405-97-6

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

17938

Références

Appl Environ Microbiol. 2015 Jun;81(11):3593-603
pubmed: 25795666
J Mol Biol. 1982 May 5;157(1):105-32
pubmed: 7108955
Sci Rep. 2017 Mar 15;7:44324
pubmed: 28295017
Lancet Infect Dis. 2016 Feb;16(2):239-51
pubmed: 26795692
J Med Chem. 2008 Apr 24;51(8):2354-62
pubmed: 18370376
mBio. 2018 Oct 9;9(5):
pubmed: 30301848
FEBS Lett. 1983 Jul 4;157(2):307-10
pubmed: 6190678
J Pept Sci. 2015 May;21(5):323-9
pubmed: 25358509
Curr Top Microbiol Immunol. 2008;322:107-31
pubmed: 18453274
Curr Top Med Chem. 2016;16(1):54-64
pubmed: 26139114
Nat Protoc. 2008;3(2):163-75
pubmed: 18274517
mBio. 2012 Jul 31;3(4):e00198-12
pubmed: 22851659
Adv Drug Deliv Rev. 2009 Nov 30;61(14):1375-85
pubmed: 19716396
Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):E1409-18
pubmed: 24706874
Appl Environ Microbiol. 2007 Oct;73(20):6620-8
pubmed: 17720841
J Biol Chem. 2001 Sep 21;276(38):35714-22
pubmed: 11473117
Biochim Biophys Acta. 1999 Dec 15;1462(1-2):201-21
pubmed: 10590309
Biochim Biophys Acta. 2014 Sep;1838(9):2260-8
pubmed: 24699372
PLoS Pathog. 2012;8(4):e1002626
pubmed: 22496652
Angew Chem Int Ed Engl. 2014 Mar 24;53(13):3392-5
pubmed: 24554486
Langmuir. 2013 Jun 4;29(22):6573-81
pubmed: 23654287
J Control Release. 2016 May 10;229:130-139
pubmed: 26993425
Clin Infect Dis. 2009 Sep 15;49(6):935-41
pubmed: 19673644
Antimicrob Agents Chemother. 2015 Sep;59(9):5288-96
pubmed: 26077259
Curr Med Chem. 2001 Jul;8(9):1137-46
pubmed: 11472245
Biochemistry. 1984 Jan 3;23(1):73-7
pubmed: 6197996
Pharmaceuticals (Basel). 2016 Sep 07;9(3):
pubmed: 27618065
Appl Environ Microbiol. 2013 Dec;79(23):7116-21
pubmed: 24038684
Curr Top Med Chem. 2016;16(11):1217-30
pubmed: 26369812
Antimicrob Agents Chemother. 2010 Aug;54(8):3079-85
pubmed: 20498310
Biochemistry. 1983 Aug 30;22(18):4280-91
pubmed: 6194817
Int J Antimicrob Agents. 2011 Jun;37(6):550-3
pubmed: 21482080
Front Cell Infect Microbiol. 2015 Feb 10;5:7
pubmed: 25713785
J Microbiol Methods. 2000 Apr;40(2):175-9
pubmed: 10699673
Expert Rev Anti Infect Ther. 2015 May;13(5):605-13
pubmed: 25746414
Curr Opin Microbiol. 2016 Oct;33:35-40
pubmed: 27318321
Biochemistry. 2010 Feb 23;49(7):1477-85
pubmed: 20082523
Yale J Biol Med. 2017 Jun 23;90(2):269-281
pubmed: 28656013
Langmuir. 2008 Jan 1;24(1):208-16
pubmed: 18052298
Antimicrob Agents Chemother. 2010 Aug;54(8):3132-42
pubmed: 20530225
Clin Microbiol Infect. 2012 Mar;18(3):268-81
pubmed: 21793988
Front Microbiol. 2016 May 26;7:788
pubmed: 27303380
J Med Microbiol. 2009 Aug;58(Pt 8):1067-1073
pubmed: 19528167
Dose Response. 2013 Jul 25;12(1):152-61
pubmed: 24659939
Nature. 2018 Apr 5;556(7699):40-41
pubmed: 29620744
Biopolymers. 2006 Feb 15;81(3):215-24
pubmed: 16261508
Annu Rev Biochem. 2009;78:119-46
pubmed: 19231985
Handb Exp Pharmacol. 2012;(211):121-33
pubmed: 23090599
Eur J Biochem. 1979 Aug 15;99(1):49-55
pubmed: 90616
J Dtsch Dermatol Ges. 2014 Dec;12(12):1121-7
pubmed: 25482696
Chem Biol. 2010 Sep 24;17(9):970-80
pubmed: 20851346
J Bacteriol. 2012 Oct;194(19):5404-12
pubmed: 22865841
Expert Rev Anti Infect Ther. 2013 Mar;11(3):297-308
pubmed: 23458769
BMC Struct Biol. 2005 Sep 30;5:18
pubmed: 16197548
Front Cell Infect Microbiol. 2015 Jan 28;5:1
pubmed: 25674541
Sci Rep. 2016 Nov 07;6:36549
pubmed: 27819280
Nat Rev Microbiol. 2006 Apr;4(4):295-305
pubmed: 16541137
PLoS Genet. 2013;9(1):e1003123
pubmed: 23300474
J Pharm Sci. 2003 Nov;92(11):2236-48
pubmed: 14603509
Clin Microbiol Infect. 2010 Jun;16(6):555-62
pubmed: 20569266
Methods Enzymol. 2012;517:387-406
pubmed: 23084949
Top Curr Chem. 2008;273:139-54
pubmed: 23605461
J Bacteriol. 2003 Mar;185(5):1485-91
pubmed: 12591863
J Dent. 2013 Sep;41(9):779-86
pubmed: 23851130
Anal Chim Acta. 2014 Feb 27;813:83-9
pubmed: 24528664
J Microbiol Methods. 2001 Mar 1;44(2):121-9
pubmed: 11165341
PLoS Pathog. 2014 May 22;10(5):e1004152
pubmed: 24852171
Curr Top Microbiol Immunol. 2008;322:207-28
pubmed: 18453278
P T. 2015 Apr;40(4):277-83
pubmed: 25859123
Antimicrob Agents Chemother. 2010 Dec;54(12):4985-91
pubmed: 20855746
PLoS One. 2012;7(8):e39373
pubmed: 22879874
Front Immunol. 2012 Aug 01;3:222
pubmed: 22870073
J Med Chem. 2016 Apr 14;59(7):3079-86
pubmed: 26958984
Cell Mol Life Sci. 2009 Dec;66(23):3821-6
pubmed: 19701717
Biochemistry. 1999 Jun 1;38(22):7235-42
pubmed: 10353835
Cell. 2014 Apr 24;157(3):539-48
pubmed: 24766804

Auteurs

Marina Berditsch (M)

Karlsruhe Institute of Technology (KIT), Institute of Organic Chemistry (IOC), Karlsruhe, 76131, Germany.

Sergii Afonin (S)

KIT, Institute of Biological Interfaces (IBG-2), Karlsruhe, 76021, Germany.

Jennifer Reuster (J)

Karlsruhe Institute of Technology (KIT), Institute of Organic Chemistry (IOC), Karlsruhe, 76131, Germany.

Hannah Lux (H)

Karlsruhe Institute of Technology (KIT), Institute of Organic Chemistry (IOC), Karlsruhe, 76131, Germany.

Kristina Schkolin (K)

Karlsruhe Institute of Technology (KIT), Institute of Organic Chemistry (IOC), Karlsruhe, 76131, Germany.

Oleg Babii (O)

KIT, Institute of Biological Interfaces (IBG-2), Karlsruhe, 76021, Germany.

Dmytro S Radchenko (DS)

Enamine Ltd., Kyiv, 02094, Ukraine.
Taras Shevchenko National University of Kyiv, Kyiv, 01601, Ukraine.

Issah Abdullah (I)

University College London (UCL), UCL School of Pharmacy, London, WC1N 1AX, United Kingdom.

Nicola William (N)

University of Leeds, School of Chemistry, Leeds, LS9 2JT, United Kingdom.

Volker Middel (V)

KIT, Institute of Toxicology and Genetics (ITG), Eggenstein-Leopoldshafen, 76344, Germany.

Uwe Strähle (U)

KIT, Institute of Toxicology and Genetics (ITG), Eggenstein-Leopoldshafen, 76344, Germany.

Andrew Nelson (A)

University of Leeds, School of Chemistry, Leeds, LS9 2JT, United Kingdom.

Klara Valko (K)

University College London (UCL), UCL School of Pharmacy, London, WC1N 1AX, United Kingdom.

Anne S Ulrich (AS)

Karlsruhe Institute of Technology (KIT), Institute of Organic Chemistry (IOC), Karlsruhe, 76131, Germany. Anne.Ulrich@kit.edu.
KIT, Institute of Biological Interfaces (IBG-2), Karlsruhe, 76021, Germany. Anne.Ulrich@kit.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH